|
1
|
Brenner H, Kloor M and Pox CP: Colorectal
cancer. Lancet. 383:1490–1502. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kopetz S, Chang GJ, Overman MJ, Eng C,
Sargent DJ, Larson DW, Grothey A, Vauthey JN, Nagorney DM and
McWilliams RR: Improved survival in metastatic colorectal cancer is
associated with adoption of hepatic resection and improved
chemotherapy. J Clin Oncol. 27:3677–3683. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kobayashi T, Masaki T, Nozaki E, Sugiyama
M, Nagashima F, Furuse J, Onishi H, Watanabe T and Ohkura Y:
Microarray analysis of gene expression at the tumor front of colon
cancer. Anticancer Res. 35:6577–6581. 2015.PubMed/NCBI
|
|
5
|
Datta D, Flaxenburg JA, Laxmanan S, Geehan
C, Grimm M, Waaga-Gasser AM, Briscoe DM and Pal S: Ras-induced
modulation of CXCL10 and its receptor splice variant CXCR3-B in
MDA-MB-435 and MCF-7 cells: Relevance for the development of human
breast cancer. Cancer Res. 66:9509–9518. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lasagni L, Francalanci M, Annunziato F,
Lazzeri E, Giannini S, Cosmi L, Sagrinati C, Mazzinghi B, Orlando
C, Maggi E, et al: An alternatively spliced variant of CXCR3
mediates the inhibition of endothelial cell growth induced by
IP-10, Mig, and I-TAC, and acts as functional receptor for platelet
factor 4. J Exp Med. 197:1537–1549. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bodnar RJ, Yates CC and Wells A: IP-10
blocks vascular endothelial growth factor-induced endothelial cell
motility and tube formation via inhibition of calpain. Circ Res.
98:617–625. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wightman SC, Uppal A, Pitroda SP, Ganai S,
Burnette B, Stack M, Oshima G, Khan S, Huang X, Posner MC, et al:
Oncogenic CXCL10 signalling drives metastasis development and poor
clinical outcome. Br J Cancer. 113:327–335. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bai M, Chen X and Ba YI: CXCL10/CXCR3
overexpression as a biomarker of poor prognosis in patients with
stage II colorectal cancer. Mol Clin Oncol. 4:23–30. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Toiyama Y, Fujikawa H, Kawamura M,
Matsushita K, Saigusa S, Tanaka K, Inoue Y, Uchida K, Mohri Y and
Kusunoki M: Evaluation of CXCL10 as a novel serum marker for
predicting liver metastasis and prognosis in colorectal cancer. Int
J Oncol. 40:560–566. 2012.PubMed/NCBI
|
|
11
|
Jiang Z, Xu Y and Cai S: CXCL10 expression
and prognostic significance in stage II and III colorectal cancer.
Mol Biol Rep. 37:3029–3036. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Groom JR and Luster AD: CXCR3 ligands:
Redundant, collaborative and antagonistic functions. Immunol Cell
Biol. 89:207–215. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Billottet C, Quemener C and Bikfalvi A:
CXCR3, a double-edged sword in tumor progression and angiogenesis.
Biochim Biophys Acta. 1836:287–295. 2013.PubMed/NCBI
|
|
14
|
Ehlert JE, Addison CA, Burdick MD, Kunkel
SL and Strieter RM: Identification and partial characterization of
a variant of human CXCR3 generated by posttranscriptional exon
skipping. J Immunol. 173:6234–6240. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang C, Zheng W and Du W: CXCR3A
contributes to the invasion and metastasis of gastric cancer cells.
Oncol Rep. 36:1686–1692. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Utsumi T, Suyama T, Imamura Y, Fuse M,
Sakamoto S, Nihei N, Ueda T, Suzuki H, Seki N and Ichikawa T: The
association of CXCR3 and renal cell carcinoma metastasis. J Urol.
192:567–574. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wu Q, Dhir R and Wells A: Altered CXCR3
isoform expression regulates prostate cancer cell migration and
invasion. Mol Cancer. 11:32012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jöhrer K, Zelle-Rieser C, Perathoner A,
Moser P, Hager M, Ramoner R, Gander H, Höltl L, Bartsch G, Greil R
and Thurnher M: Up-regulation of functional chemokine receptor CCR3
in human renal cell carcinoma. Clin Cancer Res. 11:2459–2465. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jacquelot N, Enot DP, Flament C, Vimond V,
Blattner C, Pitt JM, Yamazaki T, Roberti MP, Daillère R, Vétizou M,
et al: Chemokine receptor patterns in lymphocytes mirror metastatic
spreading in melanoma. J Clin Invest. 126:921–97. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou H, Wu J, Wang T, Zhang X and Liu D:
CXCL10/CXCR3 axis promotes the invasion of gastric cancer via
PI3K/AKT pathway-dependent MMPs production. Biomed Pharmacother.
82:479–488. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ma X, Norsworthy K, Kundu N, Rodgers WH,
Gimotty PA, Goloubeva O, Lipsky M, Li Y, Holt D and Fulton A: CXCR3
expression is associated with poor survival in breast cancer and
promotes metastasis in a murine model. Mol Cancer Ther. 8:490–498.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kawada K, Sonoshita M, Sakashita H,
Takabayashi A, Yamaoka Y, Manabe T, Inaba K, Minato N, Oshima M and
Taketo MM: Pivotal role of CXCR3 in melanoma cell metastasis to
lymph nodes. Cancer Res. 64:4010–4017. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Walser TC, Rifat S, Ma X, Kundu N, Ward C,
Goloubeva O, Johnson MG, Medina JC, Collins TL and Fulton AM:
Antagonism of CXCR3 inhibits lung metastasis in a murine model of
metastatic breast cancer. Cancer Res. 66:7701–7707. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shen D and Cao X: Potential role of CXCR3
in proliferation and invasion of prostate cancer cells. Int J Clin
Exp Pathol. 8:8091–8098. 2015.PubMed/NCBI
|
|
25
|
Aksoy MO, Yang Y, Ji R, Reddy PJ,
Shahabuddin S, Litvin J, Rogers TJ and Kelsen SG: CXCR3 surface
expression in human airway epithelial cells: Cell cycle dependence
and effect on cell proliferation. Am J Physiol Lung Cell Mol
Physiol. 290:L909–L918. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ji R, Lee CM, Gonzales LW, Yang Y, Aksoy
MO, Wang P, Brailoiu E, Dun N, Hurford MT and Kelsen SG: Human type
II pneumocyte chemotactic responses to CXCR3 activation are
mediated by splice variant A. Am J Physiol Lung Cell Mol Physiol.
294:L1187–L1196. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zipin-Roitman A, Meshel T, Sagi-Assif O,
Shalmon B, Avivi C, Pfeffer RM, Witz IP and Ben-Baruch A: CXCL10
promotes invasion-related properties in human colorectal carcinoma
cells. Cancer Res. 67:3396–3405. 2007. View Article : Google Scholar : PubMed/NCBI
|
